Dementia - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Dementia - Pipeline Review, H2 2018’, provides an overview of the Dementia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dementia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dementia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dementia

- The report reviews pipeline therapeutics for Dementia by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Dementia therapeutics and enlists all their major and minor projects

- The report assesses Dementia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Dementia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Dementia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acadia Pharmaceuticals Inc

Acorda Therapeutics Inc

Actinogen Medical Ltd

Adamed Sp z oo

AgeneBio Inc

Alector LLC

Allergan Plc

Anavex Life Sciences Corp

Asceneuron SA ...

Acadia Pharmaceuticals Inc

Acorda Therapeutics Inc

Actinogen Medical Ltd

Adamed Sp z oo

AgeneBio Inc

Alector LLC

Allergan Plc

Anavex Life Sciences Corp

Asceneuron SA

Axon Neuroscience SE

Axovant Sciences Ltd

Biogen Inc

BioXcel Therapeutics Inc

Boehringer Ingelheim GmbH

Bolder Biotechnology Inc

Cortice Biosciences Inc

CSPC NBP Pharmaceutical Co Ltd

Daewoong Pharmaceutical Co Ltd

Denali Therapeutics Inc

DiaMedica Therapeutics Inc

Dr. August Wolff GmbH & Co KG Arzneimittel

Echo Pharmaceuticals BV

Eisai Co Ltd

Eli Lilly and Co

Ensol Biosciences Inc

EVER Neuro Pharma GmbH

H. Lundbeck AS

Heptares Therapeutics Ltd

Hyundai Pharmaceutical Co Ltd

Immungenetics AG

Intellect Neurosciences Inc

Intra-Cellular Therapies Inc

IRLAB Therapeutics AB

Ironwood Pharmaceuticals Inc

Johnson & Johnson

M3 Biotechnology Inc

MediPost Co Ltd

Neuraltus Pharmaceuticals Inc

Neurimmune Holding AG

NeuroScientific Biopharmaceuticals Pty Ltd

Oryzon Genomics SA

P2D Inc

Pacific Northwest Biotechnology LLC

Pharmasum Therapeutics AS

Prana Biotechnology Ltd

ProMIS Neurosciences Inc

Prothena Corp Plc

Rodin Therapeutics Inc

Sage Therapeutics Inc

SanBio Inc

Sinil Pharmaceutical Co Ltd

Stemedica Cell Technologies Inc

Suven Life Sciences Ltd

Theranexus SAS

Vicore Pharma AB

Voyager Therapeutics Inc

WAVE Life Sciences Ltd

WhanIn Pharmaceutical Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Dementia – Overview 7

Dementia – Therapeutics Development 8

Dementia – Therapeutics Assessment 23

Dementia – Companies Involved in Therapeutics ...

Table of Contents

Table of Contents 2

Introduction 6

Dementia – Overview 7

Dementia – Therapeutics Development 8

Dementia – Therapeutics Assessment 23

Dementia – Companies Involved in Therapeutics Development 33

Dementia – Drug Profiles 60

Dementia – Dormant Projects 270

Dementia – Discontinued Products 275

Dementia – Product Development Milestones 277

Appendix 289

List of Tables

List of Tables

Number of Products under Development for Dementia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Tables

Number of Products under Development for Dementia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Products under Development by Companies, H2 2018 (Contd..5), H2 2018

Products under Development by Companies, H2 2018 (Contd..6), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Dementia – Pipeline by Acadia Pharmaceuticals Inc, H2 2018

Dementia – Pipeline by Acorda Therapeutics Inc, H2 2018

Dementia – Pipeline by Actinogen Medical Ltd, H2 2018

Dementia – Pipeline by Adamed Sp z oo, H2 2018

Dementia – Pipeline by AgeneBio Inc, H2 2018

Dementia – Pipeline by Alector LLC, H2 2018

Dementia – Pipeline by Allergan Plc, H2 2018

Dementia – Pipeline by Anavex Life Sciences Corp, H2 2018

Dementia – Pipeline by Asceneuron SA, H2 2018

Dementia – Pipeline by Axon Neuroscience SE, H2 2018

Dementia – Pipeline by Axovant Sciences Ltd, H2 2018

Dementia – Pipeline by Biogen Inc, H2 2018

Dementia – Pipeline by BioXcel Therapeutics Inc, H2 2018

Dementia – Pipeline by Boehringer Ingelheim GmbH, H2 2018

Dementia – Pipeline by Bolder Biotechnology Inc, H2 2018

Dementia – Pipeline by Cortice Biosciences Inc, H2 2018

Dementia – Pipeline by CSPC NBP Pharmaceutical Co Ltd, H2 2018

Dementia – Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018

Dementia – Pipeline by Denali Therapeutics Inc, H2 2018

Dementia – Pipeline by DiaMedica Therapeutics Inc, H2 2018

Dementia – Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, H2 2018

Dementia – Pipeline by Echo Pharmaceuticals BV, H2 2018

Dementia – Pipeline by Eisai Co Ltd, H2 2018

Dementia – Pipeline by Eli Lilly and Co, H2 2018

Dementia – Pipeline by Ensol Biosciences Inc, H2 2018

Dementia – Pipeline by EVER Neuro Pharma GmbH, H2 2018

Dementia – Pipeline by H. Lundbeck AS, H2 2018

Dementia – Pipeline by Heptares Therapeutics Ltd, H2 2018

Dementia – Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2018

Dementia – Pipeline by Immungenetics AG, H2 2018

Dementia – Pipeline by Intellect Neurosciences Inc, H2 2018

Dementia – Pipeline by Intra-Cellular Therapies Inc, H2 2018

Dementia – Pipeline by IRLAB Therapeutics AB, H2 2018

Dementia – Pipeline by Ironwood Pharmaceuticals Inc, H2 2018

Dementia – Pipeline by Johnson & Johnson, H2 2018

Dementia – Pipeline by M3 Biotechnology Inc, H2 2018

Dementia – Pipeline by MediPost Co Ltd, H2 2018

Dementia – Pipeline by Neuraltus Pharmaceuticals Inc, H2 2018

Dementia – Pipeline by Neurimmune Holding AG, H2 2018

Dementia – Pipeline by NeuroScientific Biopharmaceuticals Pty Ltd, H2 2018

Dementia – Pipeline by Oryzon Genomics SA, H2 2018

Dementia – Pipeline by P2D Inc, H2 2018

Dementia – Pipeline by Pacific Northwest Biotechnology LLC, H2 2018

Dementia – Pipeline by Pharmasum Therapeutics AS, H2 2018

Dementia – Pipeline by Prana Biotechnology Ltd, H2 2018

Dementia – Pipeline by ProMIS Neurosciences Inc, H2 2018

Dementia – Pipeline by Prothena Corp Plc, H2 2018

Dementia – Pipeline by Rodin Therapeutics Inc, H2 2018

Dementia – Pipeline by Sage Therapeutics Inc, H2 2018

Dementia – Pipeline by SanBio Inc, H2 2018

Dementia – Pipeline by Sinil Pharmaceutical Co Ltd, H2 2018

Dementia – Pipeline by Stemedica Cell Technologies Inc, H2 2018

Dementia – Pipeline by Suven Life Sciences Ltd, H2 2018

Dementia – Pipeline by Theranexus SAS, H2 2018

Dementia – Pipeline by Vicore Pharma AB, H2 2018

Dementia – Pipeline by Voyager Therapeutics Inc, H2 2018

Dementia – Pipeline by WAVE Life Sciences Ltd, H2 2018

Dementia – Pipeline by WhanIn Pharmaceutical Co Ltd, H2 2018

Dementia – Dormant Projects, H2 2018

Dementia – Dormant Projects, H2 2018 (Contd..1), H2 2018

Dementia – Dormant Projects, H2 2018 (Contd..2), H2 2018

Dementia – Dormant Projects, H2 2018 (Contd..3), H2 2018

Dementia – Dormant Projects, H2 2018 (Contd..4), H2 2018

Dementia – Discontinued Products, H2 2018

Dementia – Discontinued Products, H2 2018 (Contd..1), H2 2018

List of Figures

List of Figures

Number of Products under Development for Dementia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Figures

Number of Products under Development for Dementia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports